Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Number
Upcoming First
Relevance
Session Number
Session Datetime
MSD - Evolving Treatment Landscape in HNSCC
(ID 106)
Time
18:45 - 20:15
AstraZeneca - Emerging immuno-oncology options in metastatic NSCLC and SCLC: Clinical evidence and future perspectives
(ID 140)
Time
10:30 - 12:00
AstraZeneca - From Breast Cancer Biology to Therapy
(ID 101)
Time
08:45 - 10:15
Bristol Myers Squibb - From Rational to Daily Practice: Navigating Through 1L IO-based Treatment Options in Advanced RCC
(ID 135)
Time
08:45 - 09:45
AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
(ID 129)
Time
10:30 - 12:00
AbbVie, Inc. - A Novel Approach to Targeting c-Met in Lung Cancer
(ID 124)
Time
08:45 - 10:15
Daiichi Sankyo - Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies
(ID 118)
Time
18:45 - 20:15
Deciphera Pharmaceuticals - Changing the paradigm in the management of advanced GIST: Current treatment landscape and new horizon
(ID 153)
Time
10:30 - 12:00
MSD - Implementation of Immunotherapy in the First-Line Treatment of Esophageal, Gastroesophageal Junction and Gastric Cancers
(ID 113)
Time
08:45 - 10:15
Jazz Pharmaceuticals - Insight beyond Phase 3: does real-world evidence impact how we treat high-risk AML*? *High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
(ID 147)
Time
08:45 - 09:45
Bayer - Taking action in nmCRPC: Cases in the clinic
(ID 108)
Time
18:45 - 20:15
AstraZeneca - Mapping pathways for PARP inhibition in prostate cancer: practical considerations for clinical practice
(ID 142)
Time
18:45 - 20:15